Peter F. Orio III, DO, MS

Peter F. Orio III, DO, MS

Dana-Farber Brigham Cancer Centers / Harvard Medical School

Boston, Massachusetts

Peter F. Orio III, DO, MS, is Vice Chair of Network Operations for the Dana Farber Brigham Cancer Centers in Boston, Massachusetts. He also serves as the Director of Prostate Brachytherapy for the Dana Farber Brigham Cancer Centers and is an Associate Professor at Harvard Medical School. Dr. Orio earned his Bachelor of Arts in Biology/Psychology from the College of the Holy Cross, his Master’s of Science in Public Health from the University of Massachusetts at Amherst and his Doctor of Osteopathic Medicine degree from the University of New England College of Osteopathic Medicine. He completed his residency in radiation oncology at the University of Washington Medical Center. Dr. Orio served in the US Army as Assistant Chief of Radiation Oncology at Brooke Army Medical Center, where he rose to the rank of Lieutenant Colonel. Dr. Orio is active in the American Brachytherapy Society (ABS) and the American Society for Radiation Oncology (ASTRO), focusing his efforts on the advancement of brachytherapy for prostate cancer and the socioeconomics of medicine.

Talks by Peter F. Orio III, DO, MS

Update on the State of the Art Radiation Treatments for Prostate Cancer

Peter F. Orio III, DO, MS, discusses radiation oncology for localized prostate cancer. He focuses on a range of advanced techniques aimed at delivering high-dose radiation to the tumor while minimizing toxicity to surrounding tissues. Key modalities include Image-Guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), and adaptive radiation therapy, each providing distinct advantages in precision and dose management.

Dr. Orio discusses emerging technologies like MR-guided linear accelerators (MR-Linacs), and controversial options like proton therapy and prostate brachytherapy. He also addresses evolving advanced radiation techniques, with artificial intelligence growing in treatment planning and execution.

Despite these advances, ongoing research is necessary to validate the clinical benefits of these technologies and ensure they effectively reduce toxicity and improve patient outcomes. The overarching goal remains to provide personalized, precision radiation therapy that maximizes tumor control while minimizing harm to patients.

Read More

Rectal Spacing for All Forms of Radiation: Cryotherapy, HIFU, Tesla, and More

Peter F. Orio III, DO, MS, focuses on the management of localized prostate cancer, particularly emphasizing the use of rectal spacers to reduce radiation toxicity. In this 14-minute presentation, Orio discusses rectal spacing as a pivotal advancement in radiation oncology, enhancing the safety and efficacy of treatments by physically distancing the rectum from the prostate to minimize exposure.

Orio explores various rectal spacing techniques, including SpaceOAR, Barrigel, and BioProtect. The presentation stresses the importance of precise placement and the role of imaging, particularly MRI, in enhancing treatment accuracy and reducing complications. The variability in implant symmetry across products highlights the need to carefully select and use these technologies to avoid adverse effects.

The discussion concludes with considerations for extending the application of these technologies to other modalities, such as cryotherapy and focal laser ablation, reinforcing the broader implications of tumor spacing in oncologic treatment.

Read More

Biomarkers for Radiation Therapy

Peter F. Orio III, DO, MS, focuses on the evolving role of biomarkers in radiation oncology, particularly for prostate cancer. He asserts that biomarkers serve as biological indicators that help predict and monitor responses to treatment, thereby optimizing therapeutic outcomes and reducing toxicity.

In this 12-minute presentation, Dr. Orio categorizes radiation biomarkers into diagnostic, predictive, prognostic, and monitoring types, emphasizing their distinct roles in disease prediction, treatment response, and patient prognosis. Orio provides examples and discusses how these tools influence radiation planning and decision-making across various medical disciplines, including radiation oncology, medical oncology, and surgery.

The presentation underscores that while many biomarkers are prognostic, the future lies in their predictive capabilities, which are crucial for truly personalized treatment.

Read More

Brian Moran Distinguished Lecture: Mobilizing Moran’s Army from Seed to Shining Seed

Over the course of his career to date, Dr. Moran’s emphasis on quality of life issues and long-term outcomes for prostate cancer patients is evident, and his contributions to the fight against prostate cancer, such as performing over 30,000 prostate seed implant procedures and founding the Chicago Prostate Cancer Center, are innumerable.

Dr. Moran is a member of multiple specialty societies, including the American Society of Therapeutic Radiology and Oncology, the American College of Radiology, and the American Brachytherapy Society. To learn more about Dr. Moran, please visit his Author Page on Grand Rounds in Urology.

The inaugural lecture was given at IPCU 34 by Peter F. Orio III, DO, MS.

Read More

Join the GRU Community

- Why Join? -